Related Experiment Video
Updated: Jan 29, 2026
09:02
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
7.9K
Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection
Dorota Dybowska1, Małgorzata Pawłowska1, Dorota Kozielewicz1
1Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland.
Pharmaceuticals (Basel, Switzerland)
|January 28, 2026
Summary
Direct-acting antivirals (DAAs) offer high efficacy for hepatitis C virus (HCV) infection. However, managing drug interactions (DDIs) between DAAs and psychotropic medications is crucial for patients with mental disorders.
Area of Science:
- Hepatology
- Psychiatry
- Clinical Pharmacology
Background:
- Chronic hepatitis C virus (HCV) infection treatment has advanced significantly with direct-acting antivirals (DAAs).
- DAAs provide high efficacy and good tolerance, making them accessible to most patients, including those with comorbidities.
- HCV co-infection is common in patients with mental disorders, presenting unique treatment challenges.
Purpose of the Study:
- To highlight the clinical challenge of drug-drug interactions (DDIs) between pangenotypic DAAs and psychotropic medications.
- To emphasize the importance of understanding these DDIs for effective patient management in co-infected individuals.
Main Methods:
- Review of significant drug interactions between pangenotypic direct-acting antiviral regimens and commonly used psychotropic medications.
- Discussion of overlapping metabolic pathways contributing to potential DDIs.
Main Results:
- DAA therapy, while highly effective for HCV, can lead to significant DDIs with psychotropic drugs.
- These interactions can impact the efficacy and safety of both antiviral and psychiatric treatments.
- Knowledge of specific interactions is critical for optimizing treatment outcomes.
Conclusions:
- Managing drug interactions is a key clinical challenge when treating HCV in patients with mental disorders using DAAs.
- Awareness and careful consideration of DDIs are essential for successful patient management and therapeutic efficacy.
Related Concept Videos
01:28Drug Therapy
269
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
269
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
227
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
227
01:16Hepatic Drug Excretion: Influencing Factors
564
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
564
01:14Hepatic Drug Clearance: Role of Transporters
307
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
307
01:25Pharmacokinetics: Drug–Drug Interactions
430
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
430
01:17Hepatic Drug Excretion: Enterohepatic Cycling
2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K